Xtant Medical Holdings, Inc. Q1 2026 Earnings Call Summary

Strategic Transformation and Portfolio Optimization

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

• Management completed the divestiture of non-core hardware assets to Companion Spine for $21.4 million, allowing for a sharpened focus on the core high-margin biologics business.

• The company secured exclusive U.S. distribution rights for HEMOBLAST Bellows, marking a strategic entry into the multibillion-dollar hemostatic agent market.

• Performance in Q1 was impacted by the cessation of Q-code license revenue and headwinds in the advanced wound care market affecting amnio product revenue.

• Xtant is aggressively expanding its commercial reach by doubling regional sales reps and integrating 21 seasoned professionals from Dilon Technologies.

• The launch of Trivium Shaped expands the biologics portfolio by offering pre-shaped configurations that improve surgical workflow and consistency in the operating room.

• Management positions the company as a 'partner of choice' for hospital systems by offering a comprehensive suite across all five major orthopedic biologic categories.

• Strategic debt reduction of $13.3 million in Q1 was prioritized to lower interest expenses and improve the overall flexibility of the balance sheet.

Growth Outlook and Guidance Assumptions

• Full-year 2026 revenue guidance was raised to a range of $101 million to $105 million, reflecting the addition of HEMOBLAST and base business growth.

• Management expects biologics growth to accelerate throughout the remainder of 2026, driven by new product introductions and sales force investments.

• Gross margins are projected to return to the low 60s in the second half of 2026 as product mix improves and one-time Q1 inventory expenses subside.

• The company anticipates a recovery in the amnio and advanced wound care business during the second half of the year, following a soft first quarter.

• Future commercial strategy involves cross-selling the full biologics bag through the newly acquired Dilon sales team once initial HEMOBLAST targets are met.

Structural Changes and Financial Adjustments

• The termination of amniotic membrane license agreements at the end of 2025 due to reimbursement changes created a year-over-year margin headwind.

• Operating expenses decreased significantly following the sale of the international hardware business and Coflex assets.

• A $10.7 million final payment from Companion Spine was utilized to significantly reduce the outstanding balance on the company's revolving credit facility.

• Q1 gross margin of 57.3% was negatively impacted by excess and obsolete inventory expenses and the loss of high-margin royalty revenue.